Pharmacists can play an instrumental role in the administration of psychotropic long-acting injectable (LAI) medications (antipsychotics, naltrexone, buprenorphine) but may lack the training needed to perform this important service. This multi-faceted, on demand educational activity aims to reduce barriers and increase patient access to LAIs through a universal training program that includes, but is not limited to, appropriate patient selection, LAI preparation and administration techniques, and insights into methods to engage a patient population with serious mental illness.
Disclosure on State Training Requirements
The ability of a pharmacist to administer injectable medications is based on individual state regulations. Each state has its own unique LAI training requirements. Please review the regulations for the state you practice in to determine whether the program meets your needs and whether additional training beyond this program is required prior to administering LAI medications to patients.
Order a print copy of the pocket guide!
Download a certificate of completion after completing all 6 modules.
View AAPP's Advanced Track Psychotropic Long-Acting Injectable Program
This ACPE approved educational activity includes 5 hours of on demand recorded webinars on psychotropic LAI patient selection, pharmacology, dosing, preparation/administration/storage, key adverse effects and mitigation strategies, and building an LAI practice. Videos on LAI administration are incorporated into the curriculum to enhance learning and real-life application.
Introduction to Long-Acting Injectables and Patient Selection
Samantha Catanzano, PharmD, BCPP
Clinical Assistant Professor
The University of Texas at Austin College of Pharmacy
Austin, TX
Antipsychotic Long-Acting Injectable Pharmacology and Dosing
Megan Ehret, PharmD, MS, BCPP
Professor
University of Maryland
Baltimore, MD
Antipsychotic Long-Acting Injectable Preparation, Administration, and Storage
Christine Rarrick, MBA, PharmD, BCPP, BCPS
Clinical Pharmacy Specialist
MUSC
Charleston, SC
Antipsychotic Long-Acting Injectable Adverse Effects, Mitigation Strategies, and Monitoring
Substance Use Disorder Long-Acting Injectables: Naltrexone and Buprenorphine
Building a Long-Acting Injectable Practice
Updates to the Psychotropic Long-Acting Injectable Training Program
Megan Ehret, PharmD, MS, BCPP
Professor
University of Maryland
Baltimore, MD
| Title | Hours | Register |
|---|---|---|
| Introduction to Long-Acting Injectable Antipsychotics and Patient Selection ACPE This webinar reviews the signs, symptoms, and diagnostic criteria for serious mental illnesses; guideline recommendations for LAI ...[more] | 0.5 | View Purchase Options |
| Antipsychotic Long-Acting Injectable Pharmacology and Dosing ACPE This webinar summarizes the approved indications, mechanisms of action, key pharmacokinetic considerations, oral supplementation ...[more] | 1 | View Purchase Options |
| Antipsychotic Long-Acting Injectable Preparation, Administration, and Storage ACPE This webinar highlights key considerations for antipsychotic LAI preparation, administration, storage, and patient privacy. Videos ...[more] | 1 | View Purchase Options |
| Antipsychotic Long-Acting Injectable Adverse Effects, Mitigation Strategies, and Monitoring ACPE This webinar reviews the contraindications, warnings/precautions, common adverse effects, adverse effect mitigation strategies, and ...[more] | 0.75 | View Purchase Options |
| Substance Use Disorder Long-Acting Injectables: Naltrexone and Buprenorphine ACPE This webinar focuses on important factors related to use of LAIs for substance use disorders, such as target patient populations, ...[more] | 0.75 | View Purchase Options |
| Building a Long-Acting Injectable Practice ACPE The content in this webinar assists with building and expanding LAI clinics by outlining policies and procedures for administering ...[more] | 1 | View Purchase Options |
| Updates to the Psychotropic Long-Acting Injectable Training Program This webinar summarizes psychotropic long-acting injectable medications that have been approved since the launch of the program in ...[more] | View Purchase Options |